Backs FY25 revenue view $3B-$3.1B, consensus $3.03B. Backs FY25 adjusted EBITDA view $650M-$675M.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AMRX:
- Amneal Pharmaceuticals reports Q1 adjusted EPS 21c, consensus 15c
- AMRX Earnings this Week: How Will it Perform?
- Amneal Pharmaceuticals announces expanded coverage for Crexont
- Amneal Pharmaceuticals announces U.S. launch of Boruzu
- Amneal Pharmaceuticals (AMRX) Stock Soars 45% on Success of New Parkinson’s Treatment